🇺🇸 CRIZOTINIB in United States

2,846 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Death — 672 reports (23.61%)
  2. Neoplasm Progression — 464 reports (16.3%)
  3. Disease Progression — 284 reports (9.98%)
  4. Nausea — 263 reports (9.24%)
  5. Vomiting — 236 reports (8.29%)
  6. Malignant Neoplasm Progression — 218 reports (7.66%)
  7. Diarrhoea — 203 reports (7.13%)
  8. Off Label Use — 194 reports (6.82%)
  9. Drug Ineffective — 160 reports (5.62%)
  10. Dyspnoea — 152 reports (5.34%)

Source database →

CRIZOTINIB in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is CRIZOTINIB approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for CRIZOTINIB in United States?

Marketing authorisation holder not available in our data.